Faecal haemoglobin concentrations by gender and age: Implications for population-based screening for colorectal cancer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 5, 2012, Pages 935-940

  McDonald, Paula J ^a   Strachan, Judith A ^a   Digby, Jayne ^a   Steele, Robert J C ^a,b   Fraser, Callum G ^c  

^a Scottish Bowel Screening Centre   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Colorectal cancer; Decision limits; Faecal immunochemical test; Reference values; Screening

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; HEALTH PROGRAM; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SEX DIFFERENCE;

AGE FACTORS; AGED; CLINICAL CHEMISTRY TESTS; COHORT STUDIES; COLORECTAL NEOPLASMS; FECES; FEMALE; HEMOGLOBINS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; REFERENCE VALUES; SEX FACTORS;

EID: 84862157363     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.815     Document Type: Article

References (22)

1. Hoff G, Dominitz JA. Contrasting US and European approaches to colorectal cancer screening: which is best ? Gut 2010;59:407-14.
2. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. Br Med J 1998;317:559-65.
3. Steele RJ, McClements PL, Libby G, Black R, Morton C, Birrell J, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009;58:530-5.
4. Steele RJ, Kostouru I, McClements P, Watling C, Libby G, Weller D, et al. Effects of age, gender and deprivation on key performance indicators in a FOBT-based colorectal cancer screening programme. J Med Screen 2010;17:68-74.
5. Moss SM, Campbell C, Mellia J, Coleman D, Smith S, Parker R, et al. Performance measures in three rounds of the English bowel cancer screening pilot. Gut Epub 2011 May 10.
6. Lee TJ, Clifford GM, Rajasekhar P, Rutter MD, Kometa S, Ritchie MC, et al. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme. J Med Screen 2011;18:82-6.
7. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal cancer screening pilot programme: results of the first round. J Med Screen 2008;15:143-8.
8. Fraser CG. Fecal occult blood tests. Life savers or outdated colorectal screening tools ? Clin Lab News 2011:37:8-10.
9. Duffy MJ, Van Rossum LG, Van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia: a European Group on Tumor Markers (EGTM) position paper. Int J Cancer 2011;128:3-11.
10. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. 2010. Segnan N, Patnick J, Von Karsa L, eds. Available from: http://bookshop.europa.eu/is-bin/INTERSHOP.enfinity/WFS/EU-Bookshop-Site/ en-GB/-/EUR/ViewPublication-Start?PublicationKey=ND3210390. Accessed 30 September 2011.
11. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55.
12. Fraser CG, Mathew CM, McKay K, Carey FA, Steele RJ. Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 2008;57:1256-60.
13. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, Grazzini G, et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007;96:218-21.
14. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105:2457-64.
15. Khalid-De Bakker CA, Jonkers DM, Sanduleanu S, De Bruïne AP, Meijer GA, Janssen JB, et al. Test performance of fecal occult blood testing and sigmoidoscopy compared with colonoscopy screening for colorectal advanced adenoma. Cancer Prev Res 2011;4:1563-71.
16. Chen L-S, Yen AM, Chiu SH, Liao C-S, Chen H-H. Baseline immunochemical faecal occult blood test (iFOBT) concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011;12:551-8.
17. Fraser CG. Screening for colorectal neoplasia with faecal tests. Lancet Oncol 2011;12:516-7.
18. Clinical Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory-approved guideline, 3rd ed. Wayne, PA; CLSI, 2008.
19. Brown LF, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. Ann Clin Biochem 2008;45:604-5.
20. Rockey DC. Occult and obscure gastrointestinal bleeding: causes and clinical management. Nat Rev Gastroenterol Hepatol 2010;7:265-79.
21. Yeoh K-G, Ho K-Y, Chiu H-M. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorec-tal advanced neoplasia in asymptomatic Asian subjects. Gut 2011;60:1236-41.
22. Marshall T, Lancashire R, Sharp D, Peters TP, Cheng KK, Hamilton W. The diagnostic performance of scoring systems to identify symptomatic colorectal cancer compared to current referral guidance. Gut 2011;60:1242-8.